Lauren C. Nigro, MD, Michael J. Feldman, MD, Robin L. Foster, MD, and Andrea L. Pozez, MD
Suspected child abuse cases can be identified and repeat hospitalizations of such cases prevented using multidisciplinary teams to evaluate pediatric burns.
AMA J Ethics. 2018; 20(6):552-559. doi:
10.1001/journalofethics.2018.20.6.org1-1806.
Richard Weinmeyer, JD, MA, MPhil, Annalise Norling, Margaret Kawarski, and Estelle Higgins
Although the Safe Drinking Water Act of 1974 is effective in reducing contaminants to safe levels in public drinking water, its administration and enforcement poses challenges.
AMA J Ethics. 2017; 19(10):1018-1026. doi:
10.1001/journalofethics.2017.19.10.hlaw1-1710.
Using the patient’s worldview to challenge his or her decision and establish a treatment plan—implying the view is shared by the physician when it is not—could be seen as manipulative and deceptive.
Despite a tendency to react otherwise, there is no obvious reason to believe that economically disadvantaged people ought not to be exposed to the same levels of research risk as the rest of the population.
Public and private choices about allocation of funds for research raise a social-justice question: are these funding sources making fair decisions about where to invest their resources? The NIH has the clearest obligation to do so because it is taxpayer-supported.
The question that comes to mind when one considers the risks of a clinical trial is, “Why would anyone agree to participate?” Interviews with trial volunteers and their family members make clear that often it is the appeal of discovering something new and unknown.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018; 20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”